All In Biotech

NDA 218785 · Beone Medicines USA

Brukinsa

Zanubrutinib · Oral · Kinase Inhibitor

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jun 10, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

219

20 Phase 3, 77 recruiting

FAERS reports

4,539

3,384 serious, 505 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2026.

BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.1 Mantle Cell Lymphoma BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Waldenström's Macroglobulinemia BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) [see Clinical...

Mechanism: Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 2025 Original approval · Type 3 - New Dosage Form Accelerated approvalOrphanLabelLetterReview
  • Jun 10, 2025 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
2 products under this application
  • BRUKINSA · ZANUBRUTINIB 80MG · CAPSULE, ORAL · Prescription
  • BRUKINSA · ZANUBRUTINIB 160MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zanubrutinib" as an intervention, any sponsor and status, largest first.

All 219 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use585
  • disease progression318
  • myelosuppression254
  • fatigue249
  • anaemia247
  • white blood cell count decreased247
  • contusion241
  • platelet count decreased219
  • rash212
  • death211
  • pneumonia201
  • diarrhoea185

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
201917
202089
2021152
2022437
2023733
2024926
20251,195
2026989

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Brukinsa (Zanubrutinib)

2024 spending

$1.72B

Beneficiaries

18,031

130,764 claims

Per beneficiary

$95,633

$121.31 per unit

View as table
YearSpending
2020$12,508,807
2021$82,575,005
2022$303,322,613
2023$801,426,531
2024$1,724,363,414

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 99 on PubMed

Sponsor: BeOne Medicines (BeiGene)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.